丹麦1998-2018年因低血糖住院的流行病学趋势
该队列研究纳入丹麦1977-2018年全部糖尿病患者,分析1998-2018年因低血糖住院的发病趋势及危险因素。2003-2018年间,1型糖尿病低血糖住院发病率下降66%(IRR 0.34),2型糖尿病下降61%(IRR 0.39)。新型降糖药如SGLT2抑制剂、GLP-1受体激动剂和DPP-4抑制剂较低血糖风险,而磺脲类风险最高。
要点
- 1型糖尿病低血糖住院发病率下降66%,2型糖尿病下降61%。
- 磺脲类低血糖住院风险最高(HR 2.27),新型降糖药风险较低。
- 基础胰岛素类似物较低血糖风险低于人胰岛素和预混胰岛素。
核心结论
- 丹麦因低血糖住院的发病率在下降,新型治疗选择可能起重要作用。
- 从安全性角度,临床医生选择降糖方案时应考虑低血糖风险。
研究设计与样本
- 基于丹麦国家患者登记系统的全国性队列研究。
- 纳入1977-2018年全部糖尿病患者,分析1998-2018年因低血糖住院事件。
- 共分析66,438次低血糖住院事件,涉及641,402例1型和2型糖尿病患者。
- 采用泊松回归和线性回归分析发病率趋势,Cox比例风险模型分析危险因素。
主要发现
- 2003-2018年,1型糖尿病低血糖住院发病率下降66%(IRR 0.34 [95% CI 0.31, 0.36], p < 0.0001)。
- 2003-2018年,2型糖尿病低血糖住院发病率下降61%(IRR 0.39 [95% CI 0.36, 0.42], p < 0.0001)。
- 与人胰岛素相比,甘精胰岛素(HR 1.20 [95% CI 1.05, 1.36], p=0.0059)、地特胰岛素(HR 1.18 [95% CI 1.04, 1.32], p=0.0077)和德谷胰岛素(HR 1.04 [95% CI 0.81, 1.33], p=0.7706)的低血糖风险更低。
- 与磺脲类(HR 2.27 [95% CI 2.18, 2.37], p < 0.0001)相比,SGLT2抑制剂(HR 0.43 [95% CI 0.33, 0.56], p < 0.0001)、GLP-1受体激动剂(HR 0.51 [95% CI 0.44, 0.58], p < 0.0001)和DPP-4抑制剂(HR 0.44 [95% CI 0.38, 0.49], p < 0.0001)的低血糖风险更低。
- 人胰岛素中,长效胰岛素HR 1.38 [95% CI 1.25, 1.52], p < 0.0001;预混胰岛素HR 1.84 [95% CI 1.65, 2.05], p < 0.0001。
临床怎么用
- 临床选择降糖药物时,应优先考虑低血糖风险较低的新型药物(如SGLT2抑制剂、GLP-1受体激动剂、DPP-4抑制剂)。
- 使用磺脲类或人胰岛素(尤其是预混胰岛素)时,需警惕低血糖住院风险。
- 基础胰岛素类似物(甘精、地特、德谷)的低血糖风险低于人胰岛素和预混胰岛素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: We aimed to investigate the nationwide trends in incidence and associated risk factors, with focus on blood glucose-lowering medication, for the first hypoglycaemic episode leading to hospitalisation in Denmark among people with type 1 and 2 diabetes mellitus. METHODS: A cohort study of all people with diabetes from 1977 to 2018 experiencing hypoglycaemic episodes leading to hospitalisation in 1998-2018 was established. Data were extracted from the Danish National Patient Registry. Trends in incidence rates were investigated with Poisson regression models and linear regressions, and risk factors were investigated with Cox proportional hazards models. RESULTS: A total of 66,438 hypoglycaemic episodes leading to hospitalisation in 1998-2018 was investigated among 641,402 people with type 1 (mean ± SD age 37 ± 22 years) and type 2 diabetes (mean ± SD age 61 ± 17 years). Between 2003 and 2018, the incidence rate fell by 66% for type 1 diabetes (incidence rate ratio [IRR] 0.34 [95% CI 0.31, 0.36], p < 0.0001) and 61% for type 2 diabetes (IRR 0.39 [95% CI 0.36, 0.42], p < 0.0001). With respect to hypoglycaemic episodes, insulin glargine (HR 1.20 [95% CI 1.05, 1.36], p = 0.0059), insulin detemir (HR 1.18 [95% CI 1.04, 1.32], p = 0.0077) and insulin degludec (HR 1.04 [95% CI 0.81,1.33], p = 0.7706) seemed safer than human insulin (long-acting insulin HR 1.38 [95% CI 1.25, 1.52], p < 0.0001; combination insulins HR 1.84 [95% CI 1.65, 2.05], p < 0.0001) and, especially, sodium-glucose cotransporter 2 inhibitors (HR 0.43 [95% CI 0.33, 0.56], p < 0.0001), glucagon-like peptide 1 receptor agonists (HR 0.51 [95% CI 0.44, 0.58], p < 0.0001) and dipeptidyl peptidase 4 inhibitors (HR 0.44 [95% CI 0.38, 0.49], p < 0.0001) seemed safer than sulfonylureas (HR 2.27 [95% CI 2.18, 2.37], p < 0.0001). CONCLUSIONS/INTERPRETATION: Incidence rates of hypoglycaemic episodes leading to hospitalisation are declining in Denmark, and the advent of new treatment alternatives may play a significant role in this decline. From a safety perspective, these findings are important and should be considered by clinicians when assessing treatment options for patients.
引用
- Jensen MH, Hejlesen O, Vestergaard P, et al. Epidemiology of hypoglycaemic episodes leading to hospitalisations in Denmark in 1998-2018. Diabetologia. 2021. PMID: 34245315. doi:10.1007/s00125-021-05507-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。